|
1) Martin M. The severity and pattern of emesis following different cytotoxic agents. Oncology. 1996; 53 (suppl 1): 26-31
|
|
|
|
2) 日本癌治療学会, 編. In: 制吐薬適正使用ガイドライン. 東京: 金原出版; 2010
|
|
|
|
|
|
3) Roila1 F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010; 21 (Supple 5): 232-7
|
|
|
|
|
4) Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003; 21: 4112-9
|
|
|
|
|
|
5) McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003; 74: 17-24
|
|
|
|
|
|
6) Wong EH, Clark R, Leung E, et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol. 1995; 114: 851-9
|
|
|
|
|
|
7) Maemondo M, Masuda N, Sekine I, et al. A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Ann Oncol. 2009; 20: 1860-6
|
|
|
|
|
|
8) 味岡廣房, 森田文雄, 秋澤有四郎, 他. 新規5-HT3受容体拮抗型制吐薬パロノセトロン塩酸塩(アロキシ®静注0. 75mg)の薬理学的および薬物動態学的特長, ならびに臨床試験成績. 日薬理誌. 2010; 136: 113
|
|
|
|
|
9) Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009; 10: 115-24
|
|
|
|
|
|
10) Botrel TE, Clark OA, Clark L, et al. Efficary of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer. 2010 May 22. [Epub ahead of print]
|
|
|
|
|